AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16123739 — intervention group
Group type: EXPERIMENTAL
Intervention: DMT (high dose)
Number of subjects: 15
Study 16123739 — intervention group
Group type: EXPERIMENTAL
Intervention: S-ketamine (low dose)
Number of subjects: 15
Study 16123739 — intervention group
Group type: EXPERIMENTAL
Intervention: S-ketamine (high dose)
Number of subjects: 15
Study 15127564 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical neck dissection (RND)
Number of subjects: 76
Study 15127564 — intervention group
Group type: COMPARATOR
Intervention: Functional neck dissection (FND)
Number of subjects: 76
Study 15127564 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (RND and FND)
Number of subjects: 76
Study 15127564 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative cervical lymph nodes
Number of subjects: 76
Study 15127564 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive cervical lymph nodes
Number of subjects: 76
Study 11313302 — intervention group
Group type: EXPERIMENTAL
Intervention: CDP571 (10 or 20 mg/kg)
Number of subjects: 169
Study 11313302 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169
Study 9807987 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan plus supportive care
Number of subjects: 279
Study 9807987 — intervention group
Group type: COMPARATOR
Intervention: Supportive care alone
Number of subjects: 279
Study 7977475 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil, 125 mg twice a day for 2 days
Number of subjects: 50
Study 7977475 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime axetil, 125 mg twice a day for 10 days
Number of subjects: 50
Study 2647995 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen A (pentobarbital, prochlorperazine, and dexamethasone)
Number of subjects: 12
Study 2647995 — intervention group
Group type: COMPARATOR
Intervention: Regimen B (dexamethasone, prochlorperazine, and placebo)
Number of subjects: 12
Study 30673852 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial lesion diameter
Number of subjects: 509
Study 30673852 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavitated lesions
Number of subjects: 509
Study 30673852 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal lesions without cavitation
Number of subjects: 509
Study 30673852 — intervention group
Group type: EXPERIMENTAL
Intervention: Disappeared lesions
Number of subjects: 509
Study 30673852 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial NIHSS score
Number of subjects: 509
Study 30673852 — intervention group
Group type: EXPERIMENTAL
Intervention: Diameter of initial lesion
Number of subjects: 509
Study 30673852 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of slices showing acute lesion on DWI
Number of subjects: 509
Study 30673852 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression of white matter lesion
Number of subjects: 509
Study 30673852 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of acute lesions involving gray matter
Number of subjects: 509
Study 30673852 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesion location
Number of subjects: 509
Study 30673852 — intervention group
Group type: EXPERIMENTAL
Intervention: Diameter of acute lesion, initial number of old lacunes, anterior lesion location
Number of subjects: 509
Study 30673852 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial lesion diameter, posterior lesion location
Number of subjects: 509
Study 30673852 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction of acute lacunar lesion diameter
Number of subjects: 509
Study 28346581 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based hypnotherapy using a CD (CD group)
Number of subjects: 260
Study 28346581 — intervention group
Group type: COMPARATOR
Intervention: Individual hypnotherapy performed by qualified therapists (iHT group)
Number of subjects: 260
Study 26159609 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted Temperature Management (TTM) at 33°C
Number of subjects: 0
Study 26159609 — intervention group
Group type: COMPARATOR
Intervention: Targeted Temperature Management (TTM) at 36°C
Number of subjects: 0
Study 26159609 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to Return of Spontaneous Circulation (ROSC)
Number of subjects: 0
Study 23341981 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow mononuclear cell transplantation (BMMCT) combined with standard medical therapy (SMT)
Number of subjects: 58
Study 23341981 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy (SMT) alone
Number of subjects: 58
Study 23341981 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (BMMCT and SMT)
Number of subjects: 58
Study 20462466 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline plus Self-Administered Cognitive Behavior Therapy (SCBT)
Number of subjects: 251
Study 20462466 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus SCBT
Number of subjects: 251
Study 20462466 — intervention group
Group type: COMPARATOR
Intervention: Sertraline
Number of subjects: 251
Study 20462466 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study 18434890 — intervention group
Group type: EXPERIMENTAL
Intervention: Prestorage leukoreduced blood transfusions
Number of subjects: 268
Study 18434890 — intervention group
Group type: COMPARATOR
Intervention: Standard allogeneic blood transfusions
Number of subjects: 268
Study 16505129 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care for depression
Number of subjects: 901
Study 16505129 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 901
Study 16505129 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention patients (Collaborative care)
Number of subjects: 901
Study 12931208 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenia patients
Number of subjects: 30
Study 11128731 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized rehabilitation programme at home after stroke
Number of subjects: 41
Study 9372546 — intervention group
Group type: EXPERIMENTAL
Intervention: Porfiromycin (50 mg/M2, 45 mg/M2, 40 mg/M2) with radiation therapy (RT)
Number of subjects: 21
Study 9372546 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin C with radiation therapy (RT)
Number of subjects: 21
Study 8403155 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal meperidine 1 mg.kg‐1
Number of subjects: 50
Study 8403155 — intervention group
Group type: COMPARATOR
Intervention: 5% heavy lidocaine 1.2 to 1.4 ml intrathecally
Number of subjects: 50
Study 3512080 — intervention group
Group type: EXPERIMENTAL
Intervention: mazindol (1 mg)
Number of subjects: 30
Study 3512080 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study 30261868 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-day interactive training course on action-oriented home visits to pregnant women and infants.
Number of subjects: 78
Study 30261868 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 78
Study 27181196 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) therapy for 3 months
Number of subjects: 307
Study 27181196 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment for 3 months
Number of subjects: 307
Study 24987061 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab (in CAPOX-C arm)
Number of subjects: 164
Study 24987061 — intervention group
Group type: COMPARATOR
Intervention: Homozygous for 131H and/or 158V (Control group)
Number of subjects: 164
Study 22950591 — intervention group
Group type: EXPERIMENTAL
Intervention: Functioning Improvement Tool (FIT) home visit program (60 minutes)
Number of subjects: 28
Study 22950591 — intervention group
Group type: COMPARATOR
Intervention: Home visit using conversation alone (30 minutes)
Number of subjects: 28
Study 20398300 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 days moxifloxacin 400 mg/d with amoxycillin 1 g twice daily and lansoprasole 30 mg twice daily
Number of subjects: 150
Study 20398300 — intervention group
Group type: COMPARATOR
Intervention: 10 days moxifloxacin 400 mg/d with amoxycillin 1 g twice daily and lansoprasole 30 mg twice daily
Number of subjects: 150
Study 20398300 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin resistant strains
Number of subjects: 150
Study 20398300 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin sensitive strains
Number of subjects: 150
Study 18831984 — intervention group
Group type: EXPERIMENTAL
Intervention: Target contrast
Number of subjects: 0
Study 18831984 — intervention group
Group type: COMPARATOR
Intervention: Distractor contrast
Number of subjects: 0
Study 16143734 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg/d
Number of subjects: 463
Study 16143734 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 450 mg/d
Number of subjects: 463
Study 16143734 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 600 mg/d
Number of subjects: 463
Study 16143734 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam 1.5 mg/d
Number of subjects: 463
Study 16143734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 463
Study 11953922 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein diet (0.6 g/kg/d)
Number of subjects: 69
Study 11953922 — intervention group
Group type: COMPARATOR
Intervention: Free diet intake
Number of subjects: 69
Study 10511939 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.1 mm TurboSonics
Number of subjects: 119
Study 10511939 — intervention group
Group type: COMPARATOR
Intervention: 0.9 mm MicroTip
Number of subjects: 119
Study 7579027 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral doses of reboxetine (2, 3, 4, and 5 mg)
Number of subjects: 15
Study 7579027 — intervention group
Group type: COMPARATOR
Intervention: Reboxetine (4 mg therapeutic tablet formulation)
Number of subjects: 15
Study 7579027 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine (various doses)
Number of subjects: 15
Study 1834808 — intervention group
Group type: EXPERIMENTAL
Intervention: Toremifene (10, 20, 40, 60, 200, or 400 mg/d orally) for at least 8 weeks
Number of subjects: 107
Study 6772047 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydrazinophthalazine (Nepresol) 45 +/- 12 mg
Number of subjects: 32
Study 6772047 — intervention group
Group type: COMPARATOR
Intervention: Sodium nitroprusside
Number of subjects: 32
Study 30337189 — intervention group
Group type: EXPERIMENTAL
Intervention: Weaning at 1600 g
Number of subjects: 366
Study 30337189 — intervention group
Group type: COMPARATOR
Intervention: Weaning at 1800 g
Number of subjects: 366
Study 30337189 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 366
Study 28506538 — intervention group
Group type: EXPERIMENTAL
Intervention: Nexvax2 60 μg
Number of subjects: 108
Study 28506538 — intervention group
Group type: EXPERIMENTAL
Intervention: Nexvax2 90 μg
Number of subjects: 108
Study 28506538 — intervention group
Group type: EXPERIMENTAL
Intervention: Nexvax2 150 μg
Number of subjects: 108
Study 28506538 — intervention group
Group type: EXPERIMENTAL
Intervention: Nexvax2 150 μg (biopsy cohort)
Number of subjects: 108
Study 28506538 — intervention group
Group type: EXPERIMENTAL
Intervention: Nexvax2 300 μg
Number of subjects: 108
Study 28506538 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 28506538 — intervention group
Group type: COMPARATOR
Intervention: Placebo (biopsy cohort)
Number of subjects: 108
Study 28506538 — intervention group
Group type: EXPERIMENTAL
Intervention: Nexvax2 150 μg (MTD)
Number of subjects: 108
Study 26482674 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV vaccine-specific brochure, telephone recalls to parents who declined, and recalls to patients overdue for doses 2 and 3
Number of subjects: 814
Study 26482674 — intervention group
Group type: COMPARATOR
Intervention: General adolescent vaccine brochure (active comparison)
Number of subjects: 814
Study 24429154 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised MgSO(4) (three 500 mg doses in 1 h) alongside standard therapy
Number of subjects: 1109
Study 24429154 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous MgSO(4) (2 g in 20 min) alongside standard therapy
Number of subjects: 1109
Study 24429154 — intervention group
Group type: COMPARATOR
Intervention: Placebo control plus standard therapy alone
Number of subjects: 1109
Study 20820175 — intervention group
Group type: EXPERIMENTAL
Intervention: Message frames about weight discrimination
Number of subjects: 1114
Study 20820175 — intervention group
Group type: COMPARATOR
Intervention: Control condition with no paragraph
Number of subjects: 1114
Study 19953707 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide 30 mg PR
Number of subjects: 107
Study 19953707 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 16714635 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled room air (RA) insufflation
Number of subjects: 208
Study 16714635 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated carbon dioxide (CO2) delivery
Number of subjects: 208
Study 16714635 — intervention group
Group type: COMPARATOR
Intervention: Combined supine/prone assessment
Number of subjects: 208
Study 16714635 — intervention group
Group type: COMPARATOR
Intervention: Colonic distention in supine position
Number of subjects: 208
Study 15765277 — intervention group
Group type: EXPERIMENTAL
Intervention: Pheromone formula added to preferred fragrance
Number of subjects: 44
Study 15765277 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 11320107 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense strength training (77.8 +/- 3.4% of 1-repetition maximum) for 8 weeks, 3 days per week, two sets of 10 repetitions for six lower body exercises
Number of subjects: 24
Study 11320107 — intervention group
Group type: COMPARATOR
Intervention: Nonintervention control
Number of subjects: 24
Study 11320107 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense strength training
Number of subjects: 24
Study 9243684 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone induction
Number of subjects: 100
Study 9243684 — intervention group
Group type: COMPARATOR
Intervention: Halothane induction
Number of subjects: 100
Study 7921994 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenously added stroma related factors such as kit ligand or IL-11
Number of subjects: 0
Study 7921994 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of peripheral blood stem cells in autologous transplants
Number of subjects: 0
Study 3727190 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor training program (5 weekly lessons guided by trained physiotherapists)
Number of subjects: 50
Study 3727190 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 50
Study 30689800 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced ticagrelor maintenance dose (60 mg b.i.d)
Number of subjects: 52
Study 30689800 — intervention group
Group type: COMPARATOR
Intervention: Standard ticagrelor maintenance dose (90 mg b.i.d)
Number of subjects: 52
Study 29214415 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 days of filgrastim
Number of subjects: 142
Study 29214415 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 days of filgrastim
Number of subjects: 142
Study 29214415 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 days of filgrastim
Number of subjects: 142
Study 26764156 — intervention group
Group type: EXPERIMENTAL
Intervention: Mavoglurant (25, 50, or 100 mg twice daily)
Number of subjects: 314
Study 26764156 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 314
Study 25061127 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradialytic cycling for 24 weeks
Number of subjects: 60
Study 25061127 — intervention group
Group type: COMPARATOR
Intervention: Pedometer program for 24 weeks
Number of subjects: 60
Study 22545007 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly magazines and newsletters aimed at promotion of healthy eating
Number of subjects: 860
Study 22545007 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 860
Study 20832366 — intervention group
Group type: EXPERIMENTAL
Intervention: artesunate‐amodiaquine
Number of subjects: 827
Study 20832366 — intervention group
Group type: COMPARATOR
Intervention: artemether‐lumefantrine
Number of subjects: 827
Study 20832366 — intervention group
Group type: COMPARATOR
Intervention: fixed‐dose artesunate‐mefloquine
Number of subjects: 827
Study 20832366 — intervention group
Group type: COMPARATOR
Intervention: loose artesunate‐mefloquine
Number of subjects: 827
Study 20832366 — intervention group
Group type: COMPARATOR
Intervention: dihydroartemisinin‐piperaquine
Number of subjects: 827
Study 20832366 — intervention group
Group type: EXPERIMENTAL
Intervention: primaquine (0.75 mg/kg)
Number of subjects: 827
Study 18591401 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term hospitalization with diabetes education and support (STH)
Number of subjects: 426
Study 18591401 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonhospitalization but diabetes education and support (DES)
Number of subjects: 426
Study 18591401 — intervention group
Group type: COMPARATOR
Intervention: Control group (neither hospitalization nor education)
Number of subjects: 426
Study 18591401 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between STH and DES
Number of subjects: 426
Study 15748975 — intervention group
Group type: EXPERIMENTAL
Intervention: LCPUFA supplementation via formula containing 0.36% DHA and 0.72% ARA or human milk
Number of subjects: 243
Study 15748975 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-feeding duration
Number of subjects: 243
Study 12420014 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-oral lubricating device
Number of subjects: 34
Study 10474784 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 0
Study 8621857 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone
Number of subjects: 15
Study 8621857 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 2019665 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine (0.2 mg/inh) followed by theophylline (130 mg) with ephedrine (24 mg)
Number of subjects: 12
Study 2019665 — intervention group
Group type: EXPERIMENTAL
Intervention: Metaproterenol (0.65 mg/inh)
Number of subjects: 12
Study 2019665 — intervention group
Group type: COMPARATOR
Intervention: Placebo inhaler and tablets
Number of subjects: 12
Study 2019665 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine and theophylline with ephedrine
Number of subjects: 12
Study 2019665 — intervention group
Group type: EXPERIMENTAL
Intervention: Metaproterenol
Number of subjects: 12
Study 2019665 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7056196 — intervention group
Group type: EXPERIMENTAL
Intervention: human milk (1.6 g/100 kcal)
Number of subjects: 48
Study 7056196 — intervention group
Group type: EXPERIMENTAL
Intervention: formula 1 (2.3 g/100 kcal)
Number of subjects: 48
Study 7056196 — intervention group
Group type: EXPERIMENTAL
Intervention: formula 2 (3.0 g/100 kcal)
Number of subjects: 48
Study 7056196 — intervention group
Group type: COMPARATOR
Intervention: formula (1.6 g/100 kcal, 2.3 g/100 kcal, 3.0 g/100 kcal)
Number of subjects: 48
Study 30832681 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-layer closure of the uterine incision
Number of subjects: 2290
Study 30832681 — intervention group
Group type: COMPARATOR
Intervention: Single-layer closure of the uterine incision (control group)
Number of subjects: 2290
Study 28460575 — intervention group
Group type: EXPERIMENTAL
Intervention: Low AGE diet
Number of subjects: 0
Study 28460575 — intervention group
Group type: COMPARATOR
Intervention: High AGE diet
Number of subjects: 0
Study 26710049 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser Doppler imaging combined with clinical assessment
Number of subjects: 202
Study 26710049 — intervention group
Group type: COMPARATOR
Intervention: Standard care (clinical assessment only)
Number of subjects: 202
Study 25185149 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation program (3 months, twice-weekly, 90-min exercise sessions, total 24 sessions)
Number of subjects: 21
Study 25185149 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation program
Number of subjects: 21
Study 25185149 — intervention group
Group type: COMPARATOR
Intervention: Control group (maintained normal physical activity)
Number of subjects: 21
Study 25185149 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 21
Study 25185149 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (rehabilitation and control)
Number of subjects: 21
Study 23265749 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadriceps-sparing TKA
Number of subjects: 60
Study 23265749 — intervention group
Group type: COMPARATOR
Intervention: Standard medial parapatellar TKA
Number of subjects: 60
Study 20137596 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous flurbiprofen 100 mg before surgery (Group A)
Number of subjects: 60
Study 20137596 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous flurbiprofen 100 mg at the end of surgery (Group C)
Number of subjects: 60
Study 20137596 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group B)
Number of subjects: 60
Study 16685553 — intervention group
Group type: EXPERIMENTAL
Intervention: 48-week strength training, performed twice per week, consisting of three series of 10 repetitions of calf-rise at 75% of the 3-repetition maximum.
Number of subjects: 0
Study 16019074 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol plus laser trabeculoplasty
Number of subjects: 255
Study 16019074 — intervention group
Group type: COMPARATOR
Intervention: No initial treatment
Number of subjects: 255
Study 12136369 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezosentan (6.25 mg/h and 25 mg/h for 6 h) with cyclosporin (400 mg single dose)
Number of subjects: 12
Study 12136369 — intervention group
Group type: COMPARATOR
Intervention: Tezosentan (6.25 mg/h and 25 mg/h for 6 h) alone
Number of subjects: 12
Study 10597779 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 161
Study 10597779 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ZDV-ddC, ZDV-ddI, D4T-ddI, three-drug regimen)
Number of subjects: 161
Study 10597779 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-drug regimen (stavudine, lamivudine, ritonavir)
Number of subjects: 161